Doctorpresso will unveil Therapods, described as the world's first AI-powered earbuds for virtual group therapy, at CES 2026 in Las Vegas. The device delivers real-time emotion sensing and group interaction analysis at significantly lower costs than traditional therapy, addressing critical gaps in the global mental health system.
Therapods integrate advanced artificial intelligence and multimodal biosensing technology to track voice patterns, brainwaves, and heart rate variability with more than 90% accuracy in emotional assessment. By restoring critical nonverbal cues typically lost in remote therapy sessions, the technology overcomes one of the most significant challenges in virtual mental healthcare delivery.
The global mental health infrastructure continues to face substantial challenges, with traditional barriers including cost, stigma, and limited access creating widespread care deficiencies. Therapods aim to bridge these gaps through a scalable solution that provides personalized emotional insights while maintaining clinical-grade security and privacy standards. The technology has already received industry validation as a finalist for the 2025 GLOMO Awards at Mobile World Congress.
At CES 2026, attendees will experience live demonstrations of Therapods' emotion-sensing capabilities and virtual group therapy applications, showcasing its potential to transform digital mental healthcare. Doctorpresso, founded with a mission to make healthcare more accessible, develops AI wearables supported by multiple patents and clinical validations. The company has established itself as a leader in digital mental health by combining scientific rigor with intuitive design, ensuring both therapeutic effectiveness and user confidence.
Therapods represent a significant advancement in accessible mental health technology, according to company leadership. Hwanbo Jung, CEO of Doctorpresso, stated that by merging sophisticated AI with human-centered design, the company is breaking down traditional barriers and bringing proactive emotional support to people worldwide. Doctorpresso is actively exploring partnerships with corporations, telemedicine providers, and educational institutions to expand Therapods' reach and impact.
The company's long-term vision involves establishing a preventive mental health ecosystem where emotional wellbeing becomes an integrated component of daily life. At CES 2026, Doctorpresso will announce new collaborations and demonstrate how Therapods technology can be implemented across various industries, reinforcing its position as a global innovator in AI-powered healthcare solutions. The device's potential to make mental health support more accessible and affordable could have far-reaching implications for individuals, healthcare systems, and workplace wellness programs worldwide.
